MXPA06012615A - Uso de una composicion viscoelastica para tratamiento de presion intraocular incrementada. - Google Patents
Uso de una composicion viscoelastica para tratamiento de presion intraocular incrementada.Info
- Publication number
- MXPA06012615A MXPA06012615A MXPA06012615A MXPA06012615A MXPA06012615A MX PA06012615 A MXPA06012615 A MX PA06012615A MX PA06012615 A MXPA06012615 A MX PA06012615A MX PA06012615 A MXPA06012615 A MX PA06012615A MX PA06012615 A MXPA06012615 A MX PA06012615A
- Authority
- MX
- Mexico
- Prior art keywords
- fistula
- eye
- medium
- viscoelastic medium
- stabilized
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 25
- 206010016717 Fistula Diseases 0.000 claims abstract description 116
- 230000003890 fistula Effects 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 31
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 241000282414 Homo sapiens Species 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 230000000149 penetrating effect Effects 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000003786 sclera Anatomy 0.000 claims description 53
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 37
- 229920002674 hyaluronan Polymers 0.000 claims description 37
- 229960003160 hyaluronic acid Drugs 0.000 claims description 37
- 239000007863 gel particle Substances 0.000 claims description 25
- 150000004676 glycans Chemical class 0.000 claims description 23
- 229920001282 polysaccharide Polymers 0.000 claims description 23
- 239000005017 polysaccharide Substances 0.000 claims description 23
- 208000010412 Glaucoma Diseases 0.000 claims description 19
- 210000002159 anterior chamber Anatomy 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 210000001232 limbus corneae Anatomy 0.000 claims description 11
- 210000004127 vitreous body Anatomy 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 description 56
- 210000000795 conjunctiva Anatomy 0.000 description 20
- 239000000499 gel Substances 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 17
- 230000035515 penetration Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000001742 aqueous humor Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003190 viscoelastic substance Substances 0.000 description 6
- 206010039509 Scab Diseases 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 3
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001585 trabecular meshwork Anatomy 0.000 description 3
- 229940006076 viscoelastic substance Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 229920001605 Dextranomer Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002864 dextranomer Drugs 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Liquid Crystal (AREA)
- Liquid Crystal Display Device Control (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401182A SE0401182D0 (sv) | 2004-05-05 | 2004-05-05 | Novel use of a viscoelastic composition |
| PCT/SE2005/000663 WO2005105037A2 (en) | 2004-05-05 | 2005-05-04 | Use of a viscoelastic composition for treating increased intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06012615A true MXPA06012615A (es) | 2007-01-31 |
Family
ID=32466229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06012615A MXPA06012615A (es) | 2004-05-05 | 2005-05-04 | Uso de una composicion viscoelastica para tratamiento de presion intraocular incrementada. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8721622B2 (enExample) |
| EP (1) | EP1796624B1 (enExample) |
| JP (1) | JP4922158B2 (enExample) |
| AT (1) | ATE506940T1 (enExample) |
| AU (1) | AU2005237394B2 (enExample) |
| CA (1) | CA2565382C (enExample) |
| DE (1) | DE602005027718D1 (enExample) |
| ES (1) | ES2365621T3 (enExample) |
| MX (1) | MXPA06012615A (enExample) |
| RU (1) | RU2398566C2 (enExample) |
| SE (1) | SE0401182D0 (enExample) |
| WO (1) | WO2005105037A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
| JP5694664B2 (ja) * | 2006-09-29 | 2015-04-01 | サーモディクス，インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
| US8703119B2 (en) | 2007-10-05 | 2014-04-22 | Polygene Ltd. | Injectable biodegradable polymer compositions for soft tissue repair and augmentation |
| US8083720B2 (en) * | 2008-05-13 | 2011-12-27 | Solar Matthew S | Device and method for delivering therapeutic agents to an area of the body |
| US9339514B2 (en) * | 2008-09-12 | 2016-05-17 | Aptissen Sa | Method for treating glaucoma |
| US8715266B2 (en) * | 2008-09-12 | 2014-05-06 | Aptissen Sa | Glaucoma surgery |
| CN102405049A (zh) * | 2009-02-19 | 2012-04-04 | 帝人株式会社 | 多糖类衍生物的水凝胶 |
| US8529622B2 (en) | 2010-02-05 | 2013-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
| US8574217B2 (en) | 2010-04-08 | 2013-11-05 | Kmg Pharma, Llc | Sub-mucosal agent delivery method for the eye |
| US8652118B2 (en) | 2010-04-08 | 2014-02-18 | Kmg Pharma, Llc | Sub-mucosal agent delivery, apparatus, system and method |
| US8430862B2 (en) * | 2010-04-08 | 2013-04-30 | KMG Pharma LLC | Subconjunctival agent delivery apparatus, system and method |
| RU2432141C1 (ru) * | 2010-08-30 | 2011-10-27 | Александр Геннадьевич Савенков | Применение ирригационной жидкости в офтальмохирургии |
| RU2460517C1 (ru) * | 2011-07-14 | 2012-09-10 | Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой |
| US9216109B2 (en) | 2012-03-20 | 2015-12-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| KR101869988B1 (ko) * | 2013-03-27 | 2018-06-21 | 주식회사 엘지화학 | 점탄성 히알루론산 가교물 제조용 조성물, 및 이를 이용하여 얻은 히알루론산 가교물 |
| US9782247B2 (en) * | 2014-02-18 | 2017-10-10 | Cook Medical Technologies, LLC | Flexible embolic double filter |
| US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| CN110621320B (zh) | 2017-05-17 | 2023-03-17 | Tx医生公司 | 青光眼的治疗 |
| WO2019229719A1 (en) * | 2018-06-01 | 2019-12-05 | Sun Pharma Advanced Research Company Limited | An injection device |
| US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2774239A (en) | 1952-07-26 | 1956-12-18 | Wisconsin Alumni Res Found | Apparatus for determining dynamic mechanical properties of viscoelastic materials |
| SE442820B (sv) * | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
| US4965253A (en) * | 1987-10-14 | 1990-10-23 | University Of Florida | Viscoelastic material for ophthalmic surgery |
| US5066276A (en) * | 1988-06-21 | 1991-11-19 | Alcon Laboratories, Inc. | Method and apparatus for injecting viscous fluid into the eye to lift pre-retinal and post-retinal membrane with linear pressure control |
| US4955883A (en) | 1988-08-29 | 1990-09-11 | Diversatronics | Glaucoma needle with a thermal heat band |
| US5092837A (en) | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
| WO1992000745A1 (en) * | 1990-07-03 | 1992-01-23 | Autogenesis Technologies, Inc. | Collagen-based viscoelastic solution for visco-surgery |
| US5360425A (en) * | 1990-08-17 | 1994-11-01 | Candela Laser Corporation | Sclerostomy method and apparatus |
| US5360399A (en) * | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
| US5273056A (en) * | 1992-06-12 | 1993-12-28 | Alcon Laboratories, Inc. | Use of combinations of viscoelastics during surgery |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5811453A (en) | 1994-12-23 | 1998-09-22 | Alcon Laboratories, Inc. | Viscoelastic compositions and methods of use |
| US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
| US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
| US20020111603A1 (en) | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
| FR2756493B1 (fr) * | 1996-12-02 | 2001-04-13 | Delab | Dispositif d'administration locale de formulations solides ou semi-solides |
| FR2759577B1 (fr) | 1997-02-17 | 1999-08-06 | Corneal Ind | Implant de sclerectomie profonde |
| US6495608B1 (en) | 1997-07-29 | 2002-12-17 | Alcon Manufacturing, Ltd. | Methods of performing surgery with galactomannan polymers and borate |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6635267B1 (en) | 1998-11-10 | 2003-10-21 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same |
| ES2311455T3 (es) * | 1999-04-02 | 2009-02-16 | Fziomed, Inc. | Composiciones de poliacidos, de polimeros no ionicos de monomeros de oxido de alquileno y cationes multivalentes y su utilizacion para la reduccion de adherencias. |
| US6558342B1 (en) | 1999-06-02 | 2003-05-06 | Optonol Ltd. | Flow control device, introducer and method of implanting |
| CA2393673A1 (en) * | 1999-12-10 | 2001-06-14 | Iscience Corporation | Treatment of ocular disease |
| US20030211166A1 (en) * | 2001-07-31 | 2003-11-13 | Yamamoto Ronald K | Microparticulate biomaterial composition for medical use |
| US6375642B1 (en) | 2000-02-15 | 2002-04-23 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving a drainage of aqueous humor within the eye |
| US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
| EP1305057B1 (en) * | 2000-07-31 | 2005-06-22 | Iscience Corporation | Microparticulate biomaterial composition of hyaluronic acid for medical use |
| FR2819722B1 (fr) * | 2001-01-19 | 2006-11-24 | Corneal Ind | Utilisation de l'acide hyaluronique ou d'au moins l'un de ses sels dans le cadre d'un traitemnet chirurgical de la presbytie |
| EP1539066B1 (en) * | 2002-09-17 | 2012-11-07 | Iscience Surgical Corporation | Apparatus surgical bypass of aqueous humor |
-
2004
- 2004-05-05 SE SE0401182A patent/SE0401182D0/xx unknown
-
2005
- 2005-05-04 EP EP05740578A patent/EP1796624B1/en not_active Expired - Lifetime
- 2005-05-04 AU AU2005237394A patent/AU2005237394B2/en not_active Ceased
- 2005-05-04 MX MXPA06012615A patent/MXPA06012615A/es active IP Right Grant
- 2005-05-04 CA CA2565382A patent/CA2565382C/en not_active Expired - Lifetime
- 2005-05-04 US US11/579,621 patent/US8721622B2/en active Active
- 2005-05-04 WO PCT/SE2005/000663 patent/WO2005105037A2/en not_active Ceased
- 2005-05-04 DE DE602005027718T patent/DE602005027718D1/de not_active Expired - Lifetime
- 2005-05-04 ES ES05740578T patent/ES2365621T3/es not_active Expired - Lifetime
- 2005-05-04 AT AT05740578T patent/ATE506940T1/de not_active IP Right Cessation
- 2005-05-04 JP JP2007511320A patent/JP4922158B2/ja not_active Expired - Fee Related
- 2005-05-04 RU RU2006142861/15A patent/RU2398566C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| US20080058760A1 (en) | 2008-03-06 |
| WO2005105037A2 (en) | 2005-11-10 |
| EP1796624A2 (en) | 2007-06-20 |
| SE0401182D0 (sv) | 2004-05-05 |
| CA2565382A1 (en) | 2005-11-10 |
| EP1796624B1 (en) | 2011-04-27 |
| DE602005027718D1 (de) | 2011-06-09 |
| ES2365621T3 (es) | 2011-10-07 |
| WO2005105037A3 (en) | 2006-05-18 |
| CA2565382C (en) | 2013-12-03 |
| ATE506940T1 (de) | 2011-05-15 |
| RU2006142861A (ru) | 2008-06-20 |
| AU2005237394A1 (en) | 2005-11-10 |
| WO2005105037A8 (en) | 2006-12-21 |
| JP2007536220A (ja) | 2007-12-13 |
| RU2398566C2 (ru) | 2010-09-10 |
| JP4922158B2 (ja) | 2012-04-25 |
| AU2005237394B2 (en) | 2009-12-10 |
| US8721622B2 (en) | 2014-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2565382C (en) | Use of a viscoelastic composition for treating increased intraocular pressure | |
| JP4643561B2 (ja) | 流体を排出し、かつ眼圧を低下させるシャント装置及び同シャント装置を含むシステム | |
| AU2001245522B2 (en) | Apparatus and method for treating glaucoma | |
| RU2635320C2 (ru) | Способы и устройства для доставки лекарственного средства к глазной ткани с помощью микроиглы | |
| US20050277864A1 (en) | Injectable gel implant for glaucoma treatment | |
| US9339514B2 (en) | Method for treating glaucoma | |
| US8715266B2 (en) | Glaucoma surgery | |
| Hoopes | Sodium hyaluronate (Healon®) in anterior segment surgery: A review and a new use in extracapsular surgery | |
| RU2297815C1 (ru) | Способ хирургического лечения рефракторных глауком | |
| Van der Veen et al. | The gonioseton, a surgical treatment for chronic glaucoma | |
| EP4149400B1 (en) | Methods and compositions for reducing intraocular pressure | |
| RU2297816C1 (ru) | Способ хирургического лечения рефрактерных глауком | |
| RU2385694C1 (ru) | Способ хирургического лечения рефракторной глаукомы | |
| WO1999040933A1 (en) | Use of hyaluronidase to reduce viscoelastic related increases in intraocular pressure | |
| RU2228160C2 (ru) | Способ лечения рецидивирующей цилиохориоидальной отслойки после антиглаукоматозной операции | |
| RU2840443C1 (ru) | Способ профилактики геморрагических осложнений в хирургическом лечении больных со вторичной неоваскулярной некомпенсированной глаукомой | |
| RU2239399C1 (ru) | Дренаж для лечения неоваскулярной глаукомы и способ лечения неоваскулярной глаукомы | |
| RU2362525C1 (ru) | Способ лечения рефрактерной закрытоугольной глаукомы | |
| RU2464000C1 (ru) | Способ лечения нестабилизированной первичной глаукомы | |
| RU2585728C1 (ru) | Дренаж для офтальмологических операций | |
| RU2158569C2 (ru) | Способ глубокой субтеноновой анестезии | |
| RU2557925C1 (ru) | Биодеградируемый многослойный имплант для введения лекарственных веществ в витреальную полость глаза | |
| RU2394535C2 (ru) | Способ введения лекарственных препаратов в субтеноново пространство у пациентов с оперированной глаукомой | |
| RU2281735C1 (ru) | Способ трансхориоидального введения лекарственных препаратов при дистрофических заболеваниях заднего отдела глаза | |
| HAFEZI et al. | Évaluation de l'efficacite et de la morphologie de la sclerectomie profonde avec implant collagène dans l’espace suprachoroïdien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HH | Correction or change in general |